Closing of the first stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (March 29, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), the first stage in the Agreement was completed today, whereby a total direct investment of US$7 million was invested in IOPtima by the Acquirer, at a pre-money valuation of US$30 million.
 
To the complete article

Link to Newsroom

Comments are closed.